N’-羟基-2,2-二甲基2H香豆素6甲脒 | 283166-41-6

• 物质功能分类: 化学试剂 - 有机试剂 - 亚氨、脒
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: N’-羟基-2,2-二甲基2H香豆素6甲脒
• 英文名称: N'-hydroxy-2,2-dimethylchromene-6-carboximidamide
• CAS: 283166-41-6
• 化学式: C₁₂H₁₄N₂O₂
• 分子量: 218.255
• InChiKey: RKUXDCXGCHMDHC-UHFFFAOYSA-N

物化性质

• 沸点：
  356.3±52.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 、 N’-羟基-2,2-二甲基2H香豆素6甲脒 以40%的产率得到2-tert-Butyl-4-[3-(2,2-dimethyl-2H-chromen-6-yl)-[1,2,4]oxadiazol-5-yl]-phenol
  参考文献：
  名称：

  Solid-phase synthesis of 1,2,4-oxadiazoles

  摘要：

  The synthesis of 3,5-substituted 1,2,4-oxadiazoles on solid support is described. Benzoic acids bound to the Wang linker on a polystyrene resin are activated and allowed to react with N-hydroxyamidines. The resulting acylated N-hydroxyamidines are converted into 1,2,4-oxadiazoles at 125 degrees C. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(99)01983-8

文献信息

• HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS
  申请人：Härter Michael

  公开号：US20110301122A1

  公开（公告）日：2011-12-08

  The present application relates to novel substituted aryl compounds, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及新型取代芳基化合物，其制备方法，它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应缺氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步的治疗措施结合使用。
• Aryl compounds with aminoalkyl substituents and their use
  申请人：Härter Michael

  公开号：US20110312930A1

  公开（公告）日：2011-12-22

  The present application relates to novel aryl compounds with aminoalkyl substituents, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及具有氨基烷基取代基的新型芳基化合物，涉及其制备方法，涉及它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应低氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步的治疗措施结合使用。
• HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS
  申请人：Härter Michael

  公开号：US20130196964A1

  公开（公告）日：2013-08-01

  The present application relates to novel aryl compounds with heterocyclic substituents, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及具有杂环取代基的新型芳基化合物，其制备方法，它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应缺氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步治疗措施结合使用。
• HETEROCYCLISCH SUBSTITUIERTE ARYL-VERBINDUNGEN ALS HIF-INHIBITOREN
  申请人：Bayer Intellectual Property GmbH

  公开号：EP2356113B1

  公开（公告）日：2015-01-07
• [DE] AMINOALKYL-SUBSTITUERTE VERBINDUNGEN ALS HIF-INHIBITOREN<br/>[EN] AMINOALKYL-SUBSTITUTED COMPOUNDS AS HIF INHIBITORS<br/>[FR] COMPOSÉS SUBSTITUÉS PAR AMINOALKYLE COMME INHIBITEURS DE HIF
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2010054762A1

  公开（公告）日：2010-05-20

  Die vorliegende Anmeldung betrifft neue Aminoalkyl-substituierte Aryl-Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung zur Behandlung und/oder Prävention von Krankheiten sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prävention von Krankheiten, insbesondere zur Behandlung und/oder Prävention von hyperproliferativen und angiogenen Erkrankungen sowie solcher Erkrankungen, die durch eine metabolische Adaptation an hypoxische Zustände entstehen. Solche Behandlungen können als Monotherapie oder auch in Kombination mit anderen Arzneimitteln oder weiteren therapeutischen Maßnahmen erfolgen.